Real-World Clinical Outcomes and Prognostic Factors for Patients with Advanced Angiosarcoma who Received Systemic Treatment

摘要: Purpose Angiosarcoma is a highly aggressive mesenchymal tumor. Although systemic chemotherapy often considered for the inoperable or metastatic angiosarcoma, outcome of such treatment unsatisfactory and poorly delineated. Materials methods We reviewed electronic medical records 75 patients with angiosarcoma who were treated disease. Patients classified as having liver involvement if they had either primary hepatic lesions. Results Among evaluated, 51 male (68%) 24 (32%) cutaneous angiosarcoma. Liver was present in 28 (37.3%). A total 59 received first-line weekly paclitaxel (wPac) showed an objective response rate (ORR) 23.7% (n=14), median progression free survival (mPFS) 4.0 months (95% confidence interval [CI] 3.0-6.1), overall (mOS) 10.2 CI 7.0-14.6). without involvement, receiving wPac (n=35) significantly prolonged mPFS (5.8 vs. 3.2 months, respectively, p=0.014) tendency mOS (13.8 11.6 p=0.13) than those other regimens (n=12). second- later-line pazopanib monotherapy ORR 16.7% (n=4), 2.4 1.8-4.3) 5.4 3.5-NA). Conclusion Treatment seems to provide benefit, especially advanced involvement.